Clinical Trial Update: Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing durvalumab plus definitive chemoradiation versus placebo with chemoradiation for esophageal squamous cell carcinoma; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Esophageal Squamous Cell Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING